Hydroxyurea in Sickle Cell Disease: Coagulation and Activation in an Observational Study

Area of Science:

• Hematology
• Pharmacology

Background:

• Sickle cell disease (SCD) is characterized by a chronic hypercoagulable state.
• Hydroxyurea (HU) is a known treatment for reducing vaso-occlusive events in SCD patients.

Purpose of the Study:

• To evaluate the impact of hydroxyurea on coagulation and endothelial activation biomarkers in Pakistani SCD patients.
• To assess changes in D-dimer and soluble VCAM-1 levels following HU therapy.

Main Methods:

• A prospective observational study involved 25 SCD patients (HbSS or HbSβ-thalassemia) aged 10 years and above.
• Biomarkers (D-dimer, soluble VCAM-1, HbF) were measured at baseline and after 6 months of HU treatment.

Main Results:

• Hydroxyurea treatment led to a significant 33% reduction in D-dimer levels (P=.028).
• Soluble VCAM-1 levels did not change significantly (P=.381).
• HbF levels increased significantly (P<.001), correlating positively with HU treatment (r=.845).

Conclusions:

• Hydroxyurea therapy in Pakistani SCD patients effectively reduces D-dimer levels, suggesting a decrease in thrombotic activity.
• The observed increase in HbF confirms a known effect of HU, while VCAM-1 changes were not significant.